The use of PARPi in cancer therapy is an effective targeted approach in ovarian, breast, pancreatic, and prostate cancer subtypes with defective BRCA1/2 genes, commonly identified as having the “BRCAness phenotype” [9]. This evidence concerns the gene BRCA1 and prostate carcinoma.